The cross-border merger of BioAlliance Pharma and Topotarget is legally effective as of 22 July 2014
July 23 2014 - 2:00PM
Business Wire
Final calendar for trading on both Euronext
and NASDAQ OMX to be available soon
Regulatory News:
BioAlliance Pharma SA (Paris:BIO) (Euronext Paris – BIO), an
innovative company specialized in the development of drugs in
orphan oncology diseases, and Topotarget A/S (NASDAQ OMX Copenhagen
– TOPO), announce that the cross-border merger between the two
companies is legally effective as of 22 July 2014 to create Onxeo,
dedicated to orphan oncology diseases.
BioAlliance Pharma, as the absorbing entity, will remain
admitted to trading on Euronext Paris and will file for approval on
the secondary trading and official listing on NASDAQ OMX
Copenhagen. The final corresponding calendar will be announced
shortly. The company will then operate under the name of Onxeo.
Onxeo will aim at becoming a global leader on the fast-growing
market of orphan oncology drugs. It will hold a complementary
portfolio of advanced programs targeting severe pathologies for
which there is an unmet medical need. Onxeo will offer reinforced
market attractiveness, notably towards specialized international
investors, through a more important critical mass, a European scale
and a portfolio of high added value products.
About BioAlliance Pharma
Dedicated to cancer treatments with a focus on resistance
targeting and orphan products, BioAlliance Pharma conceives and
develops innovative products for orphan or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in
2005, BioAlliance Pharma’s ambition is to become a leading player
in these fields by coupling innovation to patient needs. The
company’s teams have the key competencies required to identify,
develop and register drugs in Europe and the USA.
BioAlliance Pharma has developed an advanced product
portfolio:
Orphan Oncology productsLivatag® (Doxorubicin Transdrug™)
(primary liver cancer): Phase III on goingValidive® (Clonidine
Lauriad®) (mucositis): Phase II on goingAMEP®/Synfoldin (invasive
melanoma): Clinical and Preclinical Phase
For more information, visit the BioAlliance Pharma web site at
www.bioalliancepharma.com
About Topotarget
Topotarget (NASDAQ OMX: TOPO) is a Danish-based
biopharmaceutical company headquartered in Copenhagen, Denmark,
dedicated to clinical development and registration of oncology
products. In collaboration with Spectrum Pharmaceuticals, Inc.,
Topotarget focuses on the development of its lead drug candidate,
belinostat, which has shown positive results in the treatment of
hematological malignancies and solid tumors, obtained by both mono-
and combination therapy.
For more information, please refer to www.topotarget.com.
Disclaimer
This communication expressly or implicitly contains certain
forward-looking statements concerning BioAlliance Pharma SA and its
business. Such statements involve certain known and unknown risks,
uncertainties and other factors, which could cause the actual
results, financial condition, performance or achievements of
BioAlliance Pharma SA to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. BioAlliance Pharma SA is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.
For a discussion of risks and uncertainties which could cause
actual results, financial condition, performance or achievements of
BioAlliance Pharma SA to differ from those contained in the
forward-looking statements, please refer to the Risk Factors
("Facteurs de Risque") section of the 2013 Reference Document filed
with the AMF on April 7, 2014, which is available on the AMF
website (http://www.amf-france.org) or on BioAlliance Pharma SA's
website (www.bioalliancepharma.com).
For further information, please contact:BioAlliance
Pharma:Judith Greciet, +33 1 45 58 76 00Chief Executive
OfficerorAlize RPCaroline Carmagnol and Sophie Colin, +33 6 64 18
99 59orTopotarget:Bo Jesper Hansen, +45 26 12 83 84Executive
Chairman of the BoardorAnders Vadsholt, +45 28 98 90 55Chief
Executive OfficerorImpact CommunicationsMichael Steen-Knudsen, +45
25 17 18 15
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Apr 2023 to Apr 2024